Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
Jennifer L. Snead(Oregon Health & Science University), Michael W. Deininger(Versiti Blood Center of Wisconsin)
Cited by 59
Related Papers
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
|Haematologica|2013|162
Guide Swap enables genome-scale pooled CRISPR–Cas9 screening in human primary cells
|Nature Methods|2018|87